Lexicon Pharmaceuticals (LXRX) has an average broker rating of 2.4, which is interpreted as a Buy, as rated by 5 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 considers that the stock is a Sell.
Lexicon Pharmaceuticals (LXRX) : Currently there are 3 street experts covering Lexicon Pharmaceuticals (LXRX) stock. The most bullish and bearish price target for the stock is $33 and $11 respectively for the short term. The average price target of all the analysts comes to $23.17. The estimated standard deviation from the target is $11.51.
Also, Equity analysts at the Brokerage firm Stifel Nicolaus maintains its rating on Lexicon Pharmaceuticals (NASDAQ:LXRX). The rating major has initiated the coverage with buy rating on the shares. The Analysts at Stifel Nicolaus raises the price target from $25 per share to $26 per share. The rating by the firm was issued on August 5, 2016.
Lexicon Pharmaceuticals (NASDAQ:LXRX): After opening at $18.46, the stock dipped to an intraday low of $18.46 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $19.35 and the buying power remained strong till the end. The stock closed at $19.07 for the day, a gain of 1.27% for the day session. The total traded volume was 2,494,392. The stocks close on the previous trading day was $18.83.
Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Companys telotristat etiprate is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is conducting a single Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients. The Companys sotagliflozin is an orally delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes. The Company has completed two Phase II clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment. It has also completed a Phase II clinical trial of sotagliflozin in type 1 diabetes patients.